Sellas Life Sciences Group (SLS) said Thursday it has dosed the first pediatric patient in the ongoing phase 2 trial of SLS009 in relapsed/refractory acute myeloid leukemia.
The study will assess the safety, tolerability and efficacy of SLS009 in combination with venetoclax and azacitidine at doses of 45 and 60 mg, the company said.
The company said it received the Rare Pediatric Disease Designation for the program from the Food and Drug Administration for the treatment of pediatric acute myeloid leukemia last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。